Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
356
resultados
Última actualización
04/10/2026 [07:34:00]
Resultados 125 a 150 de 356
Resumen de: WO2026185407A1
The present invention is directed to compositions, including post-biotic compositions, comprising cereal gruel fermented by Lactobacillus plantarum 299 and/or Lactobacillus plantarum 299v®. The compositions are useful for 5 treating diseases in human beings, including liver diseases, as well as gastrointestinal diseases and inflammatory conditions related to liver diseases. Disease treatment and treatment efficacies may be monitored based on the development in selected patient groups of one or more biomarkers, including intestinal fatty acid-binding protein (I-FABP) and C-reactive protein 10 (CRP).
Resumen de: US20260266819A1
The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating cerebral inflammation and associated sequelae thereof including cerebral vasospasm. In one embodiment, a method for treating cerebral vasospasm in a patient comprises the step of administering to the patient a PD-1 agonist, wherein a blood sample obtained from the patient comprises elevated PD-1 expression on monocytes relative to a control.
Resumen de: US20260266834A1
0000 A method for detecting proteins and/or their proteoforms is provided herein that includes adding one or more small molecule and one or more protein-binding agent to a biological sample, where a protein corona is formed on the surface of the protein-binding agent, and the proteins and/or their proteoforms in the protein corona are detected by an antibody-based technique or a proteomics technique. Also provided herein is a method for detecting one or more biomarker or a pattern of one or more biomarker associated with a disease or health spectrum condition, as well as a method of diagnosing or predicting a disease in a subject. Compositions including one or more small molecule, one or more protein-binding agent, and one or more biological sample are also provided.
Resumen de: US20260266848A1
0000 Disclosed herein are compositions, kits, and methods for identifying protein, miRNA, or metabolite biomarkers for dystonia, for treating a subject having a dystonia, for selecting a subject for a clinical trial, for selecting a therapeutic agent, for treatment of dystonia in a subject, for classifying a subject having dystonia, and for predicting responsiveness to a dystonia treatment.
Resumen de: US20260266724A1
An apparatus and method for identifying a protein or proteins in a sample of a biofluid. The identification is based on illuminating the sample with ultraviolet radiation and detecting and analyzing the resulting fluorescence. A trained model may be used to determine a protein responsible for a spectra detected from the illumination of the sample.
Resumen de: US20260266805A1
0000 A method of analyzing internal components of an organism, the method comprising a) taking an image of internal components of the organism, while said internal components are contained in vivo, and b) analyzing the internal components. Also a method of determining toxicity or efficacy of a substance, the method comprising: a. exposing an organism to one or more substances of interest; b. taking one or more images of one or more internal components of the organism, c. analyzing internal components of the organism from the images to determine the effects of the substance on the organism, and; d. using the results of the analysis to determine the toxicity or efficacy of the one or more substances.
Resumen de: US20260265365A1
The present disclosure relates to anti-interleukin-11 (IL-11) antibodies and antigen-binding fragments thereof including their use in the treatment or prevention of an IL-11 (interleukin 11) pathway disease or disorder.
Resumen de: US20260266810A1
The present invention provides a method for detecting two or more analytes in a sample, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting two or more analytes in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: US20260266811A1
The present invention relates to a method for detecting an analyte in a sample suitable for detecting the analyte over a range of concentrations, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: AU2025223493A1
The present disclosure provides nucleic acids, compositions, and methods of preventing or treating neurodegenerative disease in a subject comprising administering to the subject an agent that targets CHMP2B. In some embodiments the present disclosure provides a method of preventing or decreasing nuclear accumulation of CHMP7 in a cell comprising contacting the cell with an agent that targets expression of CHMP2B in the cell.
Resumen de: US20260266825A1
0000 Described herein is a method of immunoassay (the “PRO-C17 assay”) for measuring the levels of type XVII collagen ectodomain present in a patient sample, which method of immunoassay can be used for detecting and/or monitoring cancer and/or assessing the severity thereof in a patient. Also described are monoclonal antibodies and assay kits suitable for use in carrying out said methods.
Resumen de: US20260266808A1
The present invention is directed to assay methods and compounds and kits used in such assays.
Resumen de: WO2025093893A1
The present invention relates to methods of measuring the presence and/or levels of a combination of five biomarkers in a sample, said biomarkers being neurofilament light (NfL) polypeptide, glial fibrillary acidic protein (GFAP), β-Amyloid 1-42 (Aβ1-42), β-Amyloid 1-40 (Aβ1-40), and phosphorylated Tau (p-Tau181, pTau-231 and/or p-Tau217). The methods can be used to predict the subject's risk or likelihood of having and/or developing Alzheimer's disease, thus also provided is a method of predicting a subject's risk or likelihood of having and/or developing Alzheimer's disease, said method comprising measuring the presence of and/or the levels of the combination of five biomarkers. Further provided is a method of prognosing or diagnosing Alzheimer's disease in a subject comprising the methods of measuring the presence of and/or the levels of the combination of five biomarkers, and a method of treating Alzheimer's disease comprising predicting a subject's risk or likelihood of developing or having Alzheimer's disease using the methods of measuring the presence and/or levels of the combination of five biomarkers and administering a treatment if the risk or likelihood exceeds a threshold value.
Resumen de: EP4803610A1
The present invention relates to a biohybrid robot comprising an eye/brain organoid, a motor neuron spheroid and a muscle bundle, and a method for fabricating the same, and a versatile biohybrid robot according to the present invention may cause movement of muscle cells by an electrophysiological signal generated from the eye/brain organoid like a human motor system using light stimulation and a neurotransmitter. It is expected to be utilized in disease models that stimulate human signal transduction systems by combining various neurodegenerative disease models, such as Parkinson's and Alzheimer's disease models, with eye tumor models in the future, and be utilized in the fabrication of drug screening platforms using the operation of versatile biohybrid robots composed of biological tissues.
Resumen de: EP4804206A1
The present invention relates to a next generation sequencing (NGS) method for disease prediction through analysis of nail-derived germline mutations and somatic mutations, and a system therefor. Specifically, the present invention relates to a nail-based NGS analysis method for predicting or diagnosing a disease, comprising the steps of: isolating gDNA from nails; and analyzing the isolated gDNA using NGS.
Resumen de: JP2026144588A
【課題】中枢神経系の抗炎症剤、神経炎症を伴う中枢神経系疾患の治療剤及び神経炎症を伴う中枢神経系疾患の治療剤のスクリーニング方法の提供。【解決手段】セラミドキナーゼの機能を阻害する化合物を有効成分として含む、中枢神経系の抗炎症剤又は神経炎症を伴う中枢神経系疾患の治療剤であって、前記化合物は、セラミドキナーゼ遺伝子の発現を抑制する又はセラミドキナーゼタンパク質の活性を阻害する化合物である抗炎症剤。【選択図】なし
Resumen de: WO2015061183A1
Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
Resumen de: AU2021340971A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function.
Resumen de: WO2021176336A1
The present disclosure relates to a method of treating a disease or disorder associated with an abnormality in CNS function. Also provided is a method for diagnosing and/or identifying a subject having an abnormality in CNS function. FAM19A1 antagonists that can be used with the present disclosures are also provided.
Resumen de: WO2025049924A1
The present disclosure relates to a method for detecting or measuring the content of one or more selected biomarkers in a canine skin sample, comprising the steps of: a) applying an adhesive tape to an exposed skin target area of the canine, whereby an epidermal sample adhering to the adhesive tape is collected, and b) detecting the presence of, and/or measuring the content of, the one or more selected biomarkers in the epidermal sample obtained at step a). It further relates to method of determining the presence of a cutaneous disorder state in a canine skin, a method for the diagnosis of an atopic dermatitis state in a canine skin, a method of determining the beneficial effect of a pharmaceutical agent and/or a selected diet regimen in a canine affected with an atopic dermatitis and a kit of parts for detecting and/or measuring canine biomarkers in a canine epidermal sample.
Resumen de: WO2025042969A2
Disclosed herein are methods of selecting a candidate subject based on predicted response to an experimental treatment or therapeutic agent, and related methods of identifying subjects eligible to participate in a clinical trial that may be likely to respond to placebo. The methods disclosed herein are useful in the identification and/or selection of subjects for inclusion or exclusion from the clinical trial.
Resumen de: CN122709740A
本发明公开了一种用于阿尔茨海默病早期诊断的荧光免疫层析检测试剂盒，尤其涉及基于AI预测构象表位的纳米抗体、CRISPR‑Cas12a信号放大系统和纳米抗体阵列联合检测的试剂盒及其制备方法。本试剂盒具有AI预测构象表位的纳米抗体、CRISPR‑Cas12a信号放大系统、纳米抗体阵列多指标联合检测及智能解读系统，通过一次加样、一次层析，即可同时获得多个指标的准确信息，简化了检测流程，实现AD相关蛋白的超灵敏检测、特异性识别和疾病分期诊断。
Resumen de: WO2025129037A1
The current disclosure provides for methods and compositions for classifying subjects having different biological states. The disclosure describes a method comprising: filtering sequence data obtained from a sample from a subject based on long non-coding RNA (lncRNA) and/or pseudogene RNA (pgRNA), and/or the reference genome; determining a biological state classification of the subject by providing the filtered sequence data to one or more machine learning classifiers as input, wherein the one or more machine learning classifiers is trained to output biological state classifications based on filtered sequence data of a training data set.
Resumen de: CN122705757A
0001 本发明公开了一种TILRR‑HDAC6蛋白复合体、TILRR源性的HDAC6抑制剂及其应用。所述TILRR‑HDAC6蛋白复合体包括TILRR蛋白和HDAC6蛋白，所述TILRR蛋白特异性结合于HDAC6蛋白的去乙酰化结构域；所述TILRR蛋白的氨基酸序列如SEQ ID NO:1‑ SEQ ID NO:3所示，所述HDAC6蛋白的氨基酸序列如SEQ ID NO:4所示。本发明首次发现TILRR蛋白与HDAC6蛋白存在特异性相互作用，二者形成稳定的复合体，且TILRR特异性结合于HDAC6的去乙酰化结构域。本发明为HDAC6相关疾病的治疗提供了全新的靶点和候选药物分子，具有重要的科学意义。
Nº publicación: CN122705731A 08/09/2026
Solicitante:
深圳市药品检验研究院（深圳市医疗器械检测中心）
Resumen de: CN122705731A
0001 本发明公开了一种抗人Aβ的抗体及其应用。所述抗体含重链可变区VH和轻链可变区VL；所述VH包含HCDR1、HCDR2和HCDR3，所述VL包含LCDR1、LCDR2和LCDR3；所述HCDR1‑HCDR3分别包含如SEQ ID NO:1‑3所示的氨基酸序列，所述LCDR1‑LCDR3分别包含如SEQ ID NO:4‑6所示的氨基酸序列。本发明的抗体灵敏性高、特异性好，基于该抗体对人Aβ进行免疫检测，操作简单、灵敏度高、特异性强，可实现人Aβ的快速检测，对评估人Aβ具有重要意义。
BOPI
Sede Electrónica
